NCT03947489View on ClinicalTrials.gov

Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 4, 2019

Primary Completion Date

May 6, 2019

Study Completion Date

May 6, 2019

Conditions
Healthy
Interventions
DRUG

Sarpogrelate HCL 300mg

a single oral dose administration in healthy volunteers under fasting condition

Trial Locations (1)

Unknown

Daewoong pharmatceutical, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT03947489 - Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter